REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

368 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-02

Study Completion Date

2027-01-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Minor Stroke Therapy Evaluation

NCT03796468

Stroke

RECRUITING NA

Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis

NCT03268668

Stroke, Acute Biological Specimen Banks Biomarkers +2 more

RECRUITING

Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke

NCT02893631

Stroke, Acute

COMPLETED

Evaluation of Functional Recovery of Patients With Acute Ischemic Stroke Treated by Thrombectomy

NCT04916782

Acute Ischemic Stroke

RECRUITING

Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy

NCT06034847

Stroke, Acute Thrombotic

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The emergent reperfusion of the ischemic penumbra is the goal of acute ischemic stroke (AIS) treatment. Mechanical thrombectomy (MT) may be proposed up to 6 hours and from 6 to 24 hours after stroke onset if multimodal imaging demonstrates the presence of a substantial ischemic penumbra.

Despite the major benefit associated with MT, more than half of patients will remain disabled at 3 months. The rate of complete reperfusion after MT appears to be a major factor affecting functional outcome. However, this rate of complete reperfusion is only achieved in 50 % of the patients due to, at least in part, distal microcirculatory impairment and or erratic emboli.

In coronary artery disease, new antiplatelet agents, with a very short half-life, such as P2Y12 inhibitors (P2Y12I), have been shown to reduce in-stent thrombosis, myocardial infarction and death. The IV route for P2Y12 inhibitors administration is adapted to the stroke population who has frequently dysphagia that prevents per os drug administration. In addition, the very short half-life of the drug is quite interesting for the management of hemorrhagic complications or emergent surgical interventions and early antithrombotic secondary prevention initiation.

Hypothesis: subgroup of patients treated from 0 to 24 hours after onset with a demonstrated ischemic penumbra on perfusion imaging, the administration of P2Y12I in addition to MT and best medical management (BMM) may increase reperfusion rates and improve functional outcome compared to MT with BMM alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

experimental group will be treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cangrelor group

treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms/kg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms/kg/min IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.

Group Type EXPERIMENTAL

Cangrelor

Intervention Type DRUG

administration of cangrolor by iv befor thrombectomy

Best medical management group

treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.

Group Type ACTIVE_COMPARATOR

best medical management

Intervention Type OTHER

used yhe best medical management

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cangrelor

administration of cangrolor by iv befor thrombectomy

Intervention Type DRUG

best medical management

used yhe best medical management

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and/or MCA) proved on CTA or MRA.
* Symptoms onset \< 24h at imaging
* Indication for MT and fulfillment of the following brain imaging criteria :

1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax\>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more.

OR (if perfusion imaging not available or uninterpretable) :
2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, \<25 mL if NIHSS 6-20 and \<50 mL if NIHSS\>20

OR (if RAPID results are not considered reliable by the clinician) :
3. CORE CLINICAL MISMATCH according to the clinician evaluation
* Pre-stroke mRS ≤ 2
* NIHSS ≥ 6

Exclusion Criteria

* Contraindication to MT
* Patient over 80 years old with \>10 microbleeds on pre-treatment MRI
* Pre-existing dependency with mRS ≥3.
* Known tandem ICA-MCA occlusions requiring stenting
* ASPECT\<6 on NCCT or DWI-MRI
* Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol)
* History of previous intracranial hemorrhage
* Evidence of active bleeding or acute trauma (fracture) on examination
* Recent surgery with a significant risk of bleeding
* VKA oral anticoagulation with INR \>1.7
* Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with specific DOAC dosage ≥50 ng/ml and abnormal thrombin time for patients on dabigatran or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or rivaroxaban
* Platelet count \<100 000/ mm3
* Woman of childbearing age without a pregnancy test or with a positive serum pregnancy test
* Patient benefiting from a legal protection
* Non-membership of a national insurance scheme
* Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person
* Participation in another study regarding AIS care interfering with this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No